These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 32399253

  • 21. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 22. Novel evidence-based systemic lupus erythematosus responder index.
    Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1143-51. PubMed ID: 19714615
    [Abstract] [Full Text] [Related]

  • 23. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA, Canti V, Moiola L, Magnoni M, Rovere-Querini P, Coletto LA, Dagna L, Manfredi AA, Bozzolo EP.
    Int J Rheum Dis; 2019 Sep 15; 22(9):1752-1761. PubMed ID: 31379114
    [Abstract] [Full Text] [Related]

  • 24. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
    Philbin M, Niewoehner J, Wan GJ.
    Adv Ther; 2017 Aug 15; 34(8):1775-1790. PubMed ID: 28660550
    [Abstract] [Full Text] [Related]

  • 25. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
    Girman C, Panaccio MP, Hayes K, Niewoehner J, Wan GJ.
    Adv Ther; 2022 Jul 15; 39(7):3072-3087. PubMed ID: 35635646
    [Abstract] [Full Text] [Related]

  • 26. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB.
    J Rheumatol; 2011 Nov 15; 38(11):2395-9. PubMed ID: 21885488
    [Abstract] [Full Text] [Related]

  • 27. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, de la Torre I, Dörner T.
    Lancet; 2023 Mar 25; 401(10381):1001-1010. PubMed ID: 36848918
    [Abstract] [Full Text] [Related]

  • 28. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P, Narongroeknawin P, Chaiamnuay S, Asavatanabodee P, Pakchotanon R.
    Int J Rheum Dis; 2023 Apr 25; 26(4):667-672. PubMed ID: 36802112
    [Abstract] [Full Text] [Related]

  • 29. Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
    Goteti K, French J, Garcia R, Li Y, Casset-Semanaz F, Aydemir A, Townsend R, Mateo CV, Studham M, Guenther O, Kao A, Gastonguay M, Girard P, Benincosa L, Venkatakrishnan K.
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb 25; 12(2):180-195. PubMed ID: 36350330
    [Abstract] [Full Text] [Related]

  • 30. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE, Amoura Z, Cheah B, Hiepe F, Sullivan BA, Zhou L, Arnold GE, Tsuji WH, Merrill JT, Chung JB.
    Arthritis Rheumatol; 2018 Jul 25; 70(7):1071-1076. PubMed ID: 29513931
    [Abstract] [Full Text] [Related]

  • 31. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
    Petri MA, Martin RS, Scheinberg MA, Furie RA.
    Lupus; 2017 Jan 25; 26(1):27-37. PubMed ID: 27353505
    [Abstract] [Full Text] [Related]

  • 32. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
    Wynn D, Goldstick L, Bauer W, Zhao E, Tarau E, Cohen JA, Robertson D, Miller A.
    CNS Neurosci Ther; 2022 Mar 25; 28(3):364-371. PubMed ID: 34984839
    [Abstract] [Full Text] [Related]

  • 33. Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Sun F, Huang W, Chen J, Zhao L, Zhang D, Wang X, Wan W, Dai SM, Chen S, Li T, Ye S.
    Lupus Sci Med; 2022 Feb 25; 9(1):. PubMed ID: 35105722
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S.
    Lancet; 2018 Oct 13; 392(10155):1330-1339. PubMed ID: 30249507
    [Abstract] [Full Text] [Related]

  • 35. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB.
    Arthritis Rheum; 2006 Nov 13; 54(11):3623-32. PubMed ID: 17075807
    [Abstract] [Full Text] [Related]

  • 36. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.
    van Vollenhoven RF, Stohl W, Furie RA, Fox NL, Groark JG, Bass D, Kurtinecz M, Pobiner BF, Eastman WJ, Gonzalez-Rivera T, Gordon D.
    Lupus Sci Med; 2018 Nov 13; 5(1):e000288. PubMed ID: 30588323
    [Abstract] [Full Text] [Related]

  • 37. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S, CD1013 Study Investigators.
    Arthritis Rheumatol; 2017 Feb 13; 69(2):376-386. PubMed ID: 28130918
    [Abstract] [Full Text] [Related]

  • 38. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
    Tanaka Y, Bae SC, Bass D, Curtis P, Chu M, DeRose K, Ji B, Kurrasch R, Lowe J, Meizlik P, Roth DA.
    RMD Open; 2021 Jul 13; 7(2):. PubMed ID: 34215703
    [Abstract] [Full Text] [Related]

  • 39. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Petri M, Bruce IN, Dörner T, Tanaka Y, Morand EF, Kalunian KC, Cardiel MH, Silk ME, Dickson CL, Meszaros G, Zhang L, Jia B, Zhao Y, McVeigh CJ, Mosca M.
    Lancet; 2023 Mar 25; 401(10381):1011-1019. PubMed ID: 36848919
    [Abstract] [Full Text] [Related]

  • 40. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA, PEARL-SC Study.
    Ann Rheum Dis; 2015 Sep 25; 74(9):1667-75. PubMed ID: 24748629
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.